Rapid Communication
Copyright ©2006 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Feb 28, 2006; 12(8): 1270-1272
Published online Feb 28, 2006. doi: 10.3748/wjg.v12.i8.1270
Higher platelet P-selectin in male patients with inflammatory bowel disease compared to healthy males
J Patrik Fägerstam, Per A Whiss
J Patrik Fägerstam, Division of Radiology, Department of Medicine and Care, Faculty of Health Sciences, Linköping University, Linköping, Sweden
Per A Whiss, Division of Pharmacology, Department of Medicine and Care, Faculty of Health Sciences, Linköping University, Linköping, Sweden
Author contributions: All authors contributed equally to the work.
Supported by grants from the County Council of Östergötland, Sweden (No. 2000/080 and 2001/039)
Correspondence to: Dr PA Whiss, Division of Pharmacology, Department of Medicine and Care, Faculty of Health Sciences, SE-581 85 Linköping, Sweden. per.whiss@imv.liu.se
Telephone: +46-13-221478 Fax: +46-13-149106
Received: April 19, 2005
Revised: July 11, 2005
Accepted: July 20, 2005
Published online: February 28, 2006
Abstract

AIM: To observe if the total amount of platelet P-selectin (tP-selectin) in patients with inflammatory bowel disease (IBD) was related to disease entity or activity, 5-aminosalicylic acid (5-ASA) medication or gender.

METHODS: tP-selectin was measured by immunoassay in seventeen IBD patients and twelve healthy controls.

RESULTS: Compared to controls, there was no difference of tP-selectin in patients related to disease entity or activity and 5-ASA medication. When the groups were split according to gender the male patient group showed higher levels of tP-selectin compared to male controls (153 ng/mL vs 94 ng/mL, P< 0.05).

CONCLUSION: Increased tP-selectin levels may alter the inflammatory response and susceptibility to thromboembolic disease. As previously shown with soluble P-selectin, tP-selectin shows gender dependent differences important to consider in future studies.

Keywords: Platelet; P-selectin; Inflammatory bowel disease; 5-aminosalicylic acid; Gender